Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
Tango Therapeutics Inc. has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 4 distinct examiners across 2 distinct art units. This structure indicates a relatively focused prosecution effort, with multiple actions occasionally falling under the same examiner or within the same technical department. Such an arrangement can allow for some consistency in how the company's biological innovations are reviewed.
The busiest examiner for this portfolio is LADD, CAROLYN LOUISE, who is responsible for 2 pending office actions. Since there are 5 pending office actions in total, LADD, CAROLYN LOUISE manages a significant portion of the active workload. The remaining actions are distributed among the other 4 distinct examiners. This concentration under a single examiner within the 2 distinct art units provides an opportunity to establish a more predictable dialogue for a portion of the portfolio.
Practitioners should monitor the 2 pending office actions assigned to LADD, CAROLYN LOUISE for potential synergies in arguments or claim amendments. Because the company operates in the Biotechnology & Pharmaceuticals sector, the technical nuances are critical, and having multiple examiners means navigating several different expert opinions. However, the limitation to 2 distinct art units helps to bound the procedural environment, making the management of these filings more manageable than a more widely dispersed portfolio.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (60%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LADD, CAROLYN LOUISE | 2 | 58.6% | +47.1% |
| ROZOF, TIMOTHY R | 1 | 72.7% | +23.6% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| NOLAN, JASON MICHAEL | 1 | 66.5% | -27.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18833468 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | — |
| 18833319 | COMPOUNDS AND METHODS OF USE | ROZOF, TIMOTHY R | — |
| 18833315 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | — |
| 18740064 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | ANDERSON, REBECCA L | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18833468 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | 1629 | §112 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18833319 | COMPOUNDS AND METHODS OF USE | ROZOF, TIMOTHY R | — | §112DP | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18833315 | COMPOUNDS AND METHODS OF USE | LADD, CAROLYN LOUISE | — | §112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18740064 | HDAC INHIBITORS AND THERAPEUTIC USE THEREOF | ANDERSON, REBECCA L | — | DP | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18546312 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | NOLAN, JASON MICHAEL | 1623 | §112 | Non-Final OA | 43d overdue | Pending | Aug 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial